CTIS2024-516584-86-00招募中1 期
Multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of low-dose aspirin as an add-on to standard therapy in patients with bipolar disorder (ASPIRIN BD) - IPIN/ASPIRIN/BD
Instytut Psychiatrii I Neurologii0 个研究点目标入组 100 人开始时间: 2024年7月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- •Diagnosis of bipolar disorder (criterion verified by the qualifying physician on the basis of clinical history and criteria included in the classification of diseases ICD-10, code F31);, Current episode of depression (ICD-10 codes F31.3-F31.5);, Age 18-60 years; women and men;, Current treatment with at least one mood stabilizer recommended in bipolar disorder, except for valproates;, The patient is able to give informed consent to participate in the study;, The patient's body mass index is within the appropriate range (BMI> 18 and <40 kg / m2, where BMI = body weight (kg) / [height (m)] 2)., In women of childbearing age, a negative serum pregnancy test at screening and agreement to use highly effective contraceptive methods during the study (Women of childbearing potential (WOCBP) is defined as any woman or adolescent who has begun menstruation. A postmenopausal woman is defined as a woman who is over the age of 45 and has not had a menstrual period for at least 12 months). *Due to enzyme induction, carbamazepine may cause hormonal contraception to be ineffective, so patients of childbearing age taking carbamazepine as standard therapy should be advised to use other effective methods of contraception.
排除标准
- •Coexisting severe mental disorders (schizophrenia, dementia, addiction, OCD, depression other than in the course of BD);, Current use of non-pharmacological treatments (psychotherapy and biological treatments, i.e. electroconvulsive therapy, phototherapy, deep brain stimulation, transcranial magnetic stimulation), Taking acetylsalicylic acid in a chronic manner due to somatic diseases;, Regular use of steroid or non-steroidal anti-inflammatory drugs (occasional use of NSAIDs is allowed), methotrexate, digoxin, acetazolamide, antidiabetic drugs - insulin and drugs from the sulfonylurea group, anticoagulants (coumarin derivatives, heparin, oral anticoagulants from the group of non-vitamin K antagonists rivaroxaban, apixaban, dabigatran), thrombolytic or platelet aggregation drugs (ticlopidine, clopidogrel), Taking valproates within 7 days prior to the start of the study (due to the risk of significant interactions with ASA), Known allergy or hypersensitivity to ASA or other NSAIDs;, Pregnant or breastfeeding women;, Asthma, which, in the investigator's opinion, would increase the risk of an asthma attack; history of serious somatic disease (e.g. significant valvular heart disease, heart failure, hypertrophic cardiomyopathy, severe or worsening cardiomyopathy, clinically significant ECG abnormalities (defined as PR> 240msec, QRS complex> 110msec, QTcF> 500, ST segment depression) > 2 mm, ST-segment elevation> 1 mm, severe obstructive pulmonary disease, untreated thyroid disease, diagnosed HIV or hepatitis A, B or C, myocardial infarction in the last 6 months, insulin-dependent diabetes mellitus, gout). includes any somatic uncontrolled (in the last 3 months prior to study entry) disease states; a positive history of gastrointestinal, liver or kidney disease, or any other abnormal condition that impairs the function of these organs and may result in the possibility of altered absorption, excessive accumulation, or metabolic disorders or excretion of study medication. such as: history of major gastrointestinal surgery (e.g. gastrectomy, gastroenterostomy, bowel resection etc.) or a current diagnosis of an active gastrointestinal disease, gastric or duodenal ulceration, chronic gastrointestinal disease (e.g. ulcerative colitis, ileitis or gastrointestinal bleeding); liver damage, ie values = 3 times the upper limit of normal for at least two of the following - ALT, ASP, LDH, alkaline phosphatase, or bilirubin; impaired renal function as indicated by clinically significant abnormalities for blood urea nitrogen (= 30 mg / dL) and creatinine (= 2 mg / dL), as well as by the presence of abnormal urine components (eg Albuminuria);, A patient who received any investigational drug not authorized in the country where the clinical trial is conducted within 30 days immediately before the start of the trial., Patients with menorrhagia. Objectively heavy menstrual bleeding is defined as prolonged (>7 days) excessive blood loss of more than 80 mL per menstrual cycle. Clinical signs predictive of heavy menstrual bleeding include clots >2.5 cm in size, low serum ferritin levels, seepage and the need to change a sanitary pad or tampon more often than every hour, as well as menstrual bleeding.
研究者
相似试验
进行中（未招募）
1 期
Study on the treatment of the mild congnitive impairment due to Alzheimer's disease with Zinc SulphateEUCTR2019-000604-15-ITIVERSITÀ DEGLI STUDI G. D'ANNUNZIO CHIETI-PESCARA215
进行中（未招募）
1 期
Multicentre, randomized, double-blind, placebo-controlled, non-commercial clinical trial to evaluate the efficacy and safety of specific anti-SARS-CoV-2 immunoglobulin in the treatment of COVID-19CoronaVirus Disease 2019EUCTR2020-005410-18-PLSamodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie Samodzielny Publiczny Zaklad Opieki Zdrowotnej480
进行中（未招募）
不适用
Multicentre, randomized, double-blind, placebo-controlled clinical trial to evaluate the short-term efficacy and safety of two different treatment regimens of Betamethasone valerate 2.25 mg medicated plaster in patients with chronic tendinopathies of the upper and lower limbsEUCTR2012-005030-11-ITIBSA INSTITUT BIOCHIMIQUE SA
进行中（未招募）
1 期
Multicentre, double-blind, randomized, placebo-controlled, parallel-group, clinical trial to evaluates the clinical efficacy and safety of immunotherapy with purified major allergen Alt a 1 in patients with allergic rhinoconjunctivitis with or without mild to moderate asthma, sensitized the fungus Alternaria alternataEUCTR2010-024440-15-ESDIATER Laboratorio de Diagnostico y Aplicaciones Terapéuticas S.A.
进行中（未招募）
不适用
Multicentre, randomised, double-blind, placebo-controlled clinical study to assess the efficacy and safety of UroVaxom in chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) - Uro-Vaxom in patients with chronic prostatitis and chronic pelvic pain syndromeChronic prostatitis and chronic pelvic pain syndromeMedDRA version: 9.1Level: LLTClassification code 10009109Term: Chronic prostatitisMedDRA version: 9.1Level: LLTClassification code 10064189Term: Chronic pelvic pain syndromeEUCTR2007-004609-85-PTOM PHARMA200